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Abstract
Background: Pseudomonas aeruginosa (PA) is the most important bacterial pathogen in patients with
cystic fibrosis (CF) patients. Currently, routine bacteriological culture on selective/non- selective culture
media is the cornerstone of microbiological detection. The aim of this study was to compare isolation rates
of PA by conventional culture and molecular (PCR) detection directly from sputum.
Methods: Adult patients (n = 57) attending the regional adult CF centre in Northern Ireland, provided
fresh sputum following airways clearance exercise. Following processing of the specimen with sputasol (1:1
vol), the specimen was examined for the presence of PA by plating onto a combination of culture media
(Pseudomonas isolation agar, Blood agar & McConkey agar). In addition, from the same specimen, genomic
bacterial DNA was extracted (1 ml) and was amplified employing two sequence-specific targets, namely (i)
the outer membrane protein (oprL) gene locus and (ii) the exotoxin A (ETA) gene locus.
Results: By sputum culture, there were 30 patients positive for PA, whereas by molecular techniques,
there were 35 positive patients. In 39 patients (22 PA +ve & 17 PA -ve), there was complete agreement
between molecular and conventional detection and with both PCR gene loci. The oprL locus was more
sensitive than the ETA locus, as the former was positive in 10 more patients and there were no patients
where the ETA was positive and the oprL target negative. Where a PCR +ve/culture -ve result was
recorded (10 patients), we followed these patients and recorded that 5 of these patients converted to
being culture-positive at times ranging from 4–17 months later, with a mean lag time of 4.5 months.
Conclusions: This study indicates that molecular detection of PA in sputum employing the oprL gene
target, is a useful technique in the early detection of PA, gaining on average 4.5 months over conventional
culture. It now remains to be established whether aggressive antibiotic intervention at this earlier stage,
based on PCR detection, has any significant benefits on clinical outcome.
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Introduction
Cystic fibrosis [CF] is the most commonly inherited fatal
disease in persons originating from a white and European
background, currently affecting approximately 30,000
adults and children in the US [1]. The defective gene car-
rying the mutation is carried in one in every 31 Americans
[one in 28 Caucasians], equating to more than 10 million
people being a symptomless carrier of the defective gene
[1]. It is an autosomal recessive condition whereby two
alleles carrying a polymorphism in the cystic fibrosis
transmembrane conductance regulator [CFTR] gene phe-
notypically manifest the disease state through a variety of
multiorgan problems, associated with a pharmacological
disfunction to regulate sodium and chloride secretion
across cell membranes. The most common complication
of CF is the recurrence of chronic chest infections usually
caused by bacterial pathogens [2]. CF patients continue to
suffer from recurrent and chronic respiratory tract infec-
tions and most of their morbidity and mortality is due to
such infections throughout their life [3]. These infections
are usually dominated by Gram-negative organisms, espe-
cially by the pseudomonads, including Pseudomonas aeru-
ginosa,  Burkholderia cepacia and  Stenotrophomonas
maltophilia. However, with modern antibiotic manage-
ment with improved antimicrobial agents, such as the
aminoglycosides and carbapenems, CF patients have an
improved survival, resulting in more adults in
employment.
Previous studies have described alternative laboratory
markers to conventional bacteriological culture for the
detection of Pseudomonas aeruginosa in CF patients.[4,5]
These markers have included serological testing of CF
patients' sera for the presence of antibody to P. aerugi-
nosa,[4] as well as molecular detection of DNA signature
sequences of P. aeruginosa in CF patients [5]. Presently, the
routine employment of molecular (PCR) detection of P.
aeruginosa directly from the sputum of CF patients in the
UK and Ireland is uncommon. Most clinical microbiology
laboratories in the UK and Ireland, which support a CF
centre, have developed standard operating procedures
(SOPs) for the isolation of this organism from patients'
sputum. Hence, it was the aim of this study to compare
the conventional and molecular detection of P. aeruginosa
from the sputum of adult patients attending the adult cen-
tre in Northern Ireland, as well as to estimate the lag time
of conventional culture to detection, compared with
molecular (PCR) detection.
Materials & Methods
Qualitative conventional detection of Pseudomonas 
aeruginosa from sputum
Duplicate sputa (1 ml minimum) specimens were col-
lected from 57 adult patients with a well characterized his-
tory of CF in sterile (100 ml) plastic disposable
containers. Sputum was collected immediately after a
standardized session of physiotherapy and was stored at
ambient temperature and was processed within 4 h from
collection. Fresh sputum (1 ml min) was mixed with an
equal mass (1:1) of Sputasol (Oxoid SR089A, Oxoid Ltd.,
Poole, England) and was incubated in a water bath at
37°C for 15 min, before further qualitative processing for
the detection of Pseudomonas aeruginosa. Processed sputa
(10 µ l) were inoculated and incubated, onto several selec-
tive media for the isolation of Pseudomonas aeruginosa,
including:- Columbia Blood Agar (Oxoid CM0331) sup-
plemented with 5% (v/v) defribinated horse blood, Mac-
Conkey Agar (Oxoid CM0007) and Pseudomonas Isolation
Agar (PIA) (Oxoid CM0559 + SR0102). All media were
incubated aerobically at 37°C for 48 h, unless otherwise
stated. The PIA plates were incubated at room temperature
for a further three days following initial 48 hrs incubation.
In addition, all different phenotypes from the sputum of
each patient were identified phenotypically employing a
combination of conventional identification methods (e.g.
oxidase), as well as the API Identification schemes (API
20NE, API 20E) (Biomérieux, Les Halles, France).
Molecular (PCR) detection of Pseudomonas aeruginosa 
from sputum
DNA extraction
All DNA isolation procedures were carried out in a Class
II Biological Safety Cabinet (MicroFlow, England) in a
room physically separated from that used to set up nucleic
acid amplification reaction mixes and also from the "post-
PCR" room in accordance with the Good Molecular Diag-
nostic Procedures (GMDP) guidelines of Millar et al[6], in
order to minimise contamination and hence the possibil-
ity of false positive results. Bacterial genomic DNA was
extracted directly from the patients' sputum, as well as
from the reference strain Pseudomonas aeruginosa
(Schroeter; Migula) ATCC 27853, by employment of the
Roche High Purity PCR Template Preparation Kit (Roche,
England), in accordance with the manufacturer's instruc-
tions. Extracted DNA was stored at -80°C prior to PCR
amplification. For each batch of extractions, a negative
extraction control containing all reagents minus sputum,
was performed, as well as an extraction positive control
with P. aeruginosa.
PCR amplification
All reaction mixes were set up in a PCR hood in a room
separate from that used to extract DNA and the amplifica-
tion and post-PCR room in order to minimise contamina-
tion. Initially PCR amplification conditions were
optimised by separately varying magnesium chloride con-
centration, annealing temperature, primer concentration
and DNA template concentration. Following optimisa-
tion, reaction mixes (100 µl) were set up as follows:-10
mM Tris-HCl, pH 8.3, 50 mM KCl, 2.5 mM MgCl2, 200Annals of Clinical Microbiology and Antimicrobials 2004, 3:21 http://www.ann-clinmicrob.com/content/3/1/21
Page 3 of 5
(page number not for citation purposes)
µM (each) dATP, dCTP, dGTP and dTTP; 1.25 U of Taq
DNA polymerase (Amplitaq; Perkin Elmer), 0.1 µM
(each) of the each set of primers (exoA &oprL) (Table 1)
and 4 µl of DNA template. The reaction mixtures follow-
ing a "hot start" were subjected to the following empiri-
cally optimized thermal cycling parameters in a Perkin
Elmer 2400 thermocycler: 96°C for 5 min followed by 40
cycles of 96°C for 1 min, 55°C for 1 min, 72°C for 1 min,
followed by a final extension at 72°C for 10 min. Positive
(P. aeruginosa ATCC 27853 DNA) and multiple negative
(water) amplification controls were included in every set
of PCR reactions. In addition, a broad-range/universal
PCR was employed with each sputum to demonstrate suc-
cessful extraction of bacterial DNA from the specimen, as
well as lack of PCR inhibition, by employing the highly
conserved 16S rDNA primers, PSL/PSR (Table 1), as previ-
ously described [7]. Any sputum which failed to amplify
this locus was re-extracted and amplified until a positive
signal was obtained.
Detection of amplicons
Following amplification, aliquots (10 µl) were removed
from each reaction mixture and examined by electro-
phoresis (80 V, 45 min) in gels composed of 2% (w/v)
agarose (Gibco, UK) in TAE buffer (40 mM Tris, 20 mM
acetic acid, 1 mM EDTA, pH 8.3), stained with ethidium
bromide (5 µg/100 ml). Gels were visualised under UV
illumination using a gel image analysis system (UVP
Products, England) and all images archived as digital
graphic files (*.bmp). Where a band was visualized at the
correct expected size for either exoA or oprL loci, the speci-
men was considered positive for P. aeruginosa.
Results and Discussion
A comparison of the occurrence of P. aeruginosa in
patients' sputum by conventional and molecular tech-
niques is shown (Table 2). By culture, there were 30
patients positive for P. aeruginosa, whereas by molecular
techniques, there were 35 positive patients. In 39 patients
(22 P aeruginosa [PA] positive [+ve] & 17 P. aeruginosa [PA]
negative [-ve]), there was complete agreement between
molecular and conventional detection techniques. The
oprL locus was more sensitive than the ETA locus, as the
former was positive in 10 more patients and there were no
patients where the ETA was positive and the oprL target
negative, However, there were five patients who were cul-
ture positive but PCR -ve by both gene targets. Given that
the universal 16S rDNA PCR was positive for these spu-
tum specimens and that the appropriate molecular con-
trols were working optimally, this may accounted for by
potential phenotypic misidentification of P. aeruginosa,
which has been recently described.[10] Alternatively, dis-
crepant results (PCR+ve/culture-ve) could reflect true P.
aeruginosa colonization with a false-negative culture result
due to sample overgrowth by other bacteria or to the pres-
ence of non-cultivable organisms or auxotrophic muta-
tions in the organism. Where a PCR +ve/culture -ve result
was recorded (10 patients), we followed these patients
and recorded that five of these patients converted to being
culture-positive at times ranging from 4–17 months later,
with a mean lag time of 4.5 months, whereas the remain-
ing five patients remained negative for P. aeruginosa.
In this study, two PCR assays were performed individually
for the molecular detection of P. aeruginosa directly from
the sputum of patients with CF. Two gene loci were tar-
geted, as specific markers of P. aeruginosa, namely the exo-
toxin A (ETA) gene and the outer membrane lipoprotein
(oprL) gene. ETA is produced by the majority of P. aerugi-
nosa strains and can inhibit eucaryotic protein biosynthe-
sis at the level of polypeptide chain elongation factor 2,
similarly to diphtheria toxin.[9] OprL is an outer mem-
brane lipoprotein which has been implicated in efflux
transport systems, as well as affecting cell permeability.[8]
Pseudomonas aeruginosa is the most important bacterial
pathogen in patients with CF [11], as demonstrated with
high prevalence data in most of the National CF Regis-
Table 1: Oligonucletoides and optimised experimental PCR amplification conditions
Target Gene locus Primer 5'-----------------------3' Optimum MgCl2 
concentration 
(mM)
Annealing 
temperature
Size of 
Amplicon 
(bp)
Eubacteria [7] 16S rRNA f: 5'-AGG ATT AGA TAC CCT GGT AGT CCA-3' 2.5 55°C 312
r: 5'-ACT TAA CCC AAC ATC TCA CGA CAC-3'
Pseudomonas 
aeruginosa [8]
oprL1 f: 5'-ATG GAA ATG CTG AAA TTC GGC-3' 2.5 55°C 504
r: 5'-CTT CTT CAG CTC GAC GCG ACG-3'
Pseudomonas 
aeruginosa [9]
exoA2 f: 5'-GAC AAC GCC CTC AGC ATC ACC AGC-3' 2.5 72°C 396
r: 5'-CGC TGG CCC ATT CGC TCC AGC GCT-3'
1, outer membrane lipoprotein; 2, exotoxin A.Annals of Clinical Microbiology and Antimicrobials 2004, 3:21 http://www.ann-clinmicrob.com/content/3/1/21
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tries. Chronic Pseudomonas colonisation of the major air-
ways leading to delibating exacerbations of pulmonary
infection, is the major cause of morbidity and mortality in
patients with CF, hence it is important to be able to relia-
bly detect P. aeruginosa from patients' sputum. Emerson et
al. [12] recently published their findings of a US Cystic
Fibrosis Foundation (CFF) registry-based study, which
showed that infection related to P. aeruginosa was a major
predictor of morbidity and mortality, whereby the 8-year
risk of death parameter was 2.6 times higher in patients
who had positive sputum cultures for this organism, as
well as having a significantly lower percent predicted
forced expiratory volume (FEV1). These workers sug-
gested that early interventions may help decrease associ-
ated morbidity and mortality of young patients with CF.
More recently, Rosenfeld et al. [13] described the patho-
physiology and risk factors for early P. aeruginosa infection
in CF. These workers suggested that chronic lower airway
infection with P. aeruginosa is associated with significant
morbidity and mortality among CF patients [13]. How-
ever, they suggested that first acquisition of P. aeruginosa
does not appear to cause an immediate and rapid decline
in lung function, as early isolates are generally non-
mucoid, antibiotic-sensitive and present at low densities,
suggesting a possible "window of opportunity" for early
intervention, as they describe [13]. This study also con-
cluded that there are no controlled trials demonstrating
clinical benefit in young children following early inter-
vention, particularly for anti-pseudomonal therapy, as
well as the long-term safety profile and optimal drug
regimen.[13]
It is therefore important that primary diagnostic bacteriol-
ogy laboratories have the ability to detect transient and
early Pseudomonas colonization as early as possible, so that
(i) aggressive antibiotic regimes may be considered,(ii).
the patient is managed optimally, in an attempt to avoid
early biofilm formation and chronic colonization with
Pseudomonas and (iii) appropriate infection control pre-
cautions are considered. More recently, West et al. showed
by a combination of serum IgG, IgA and IgM anti P. aeru-
ginosa antibodies, in conjunction with these authors' Wis-
consis Cystic Fibrosis Radiograph score, that P. aeruginosa
infections occurred approximately 6–12 months before
the organism was recovered from respiratory secre-
tions.[4] In addition, this study demonstrated that mixing
of young child with older chronically colonised children
was associated with a significantly increased risk of P. aer-
uginosa acquisition.
Given that not all laboratories employ molecular detec-
tion methods for Pseudomonas aeruginosa, either from cul-
ture plates or patients' sputum, small numbers of
Pseudomonas colonies (n = 1–2) may therefore be missed
when present in the early stages of colonization preceding
infection of the patient's airways, particularly where such
single colonies are mixed alongside other phenotypically
similar genera on the primary culture plate.[14]
Pragmatic, practical and cost implications leave it impos-
sible to qualitatively identify the total bacterial microflora
present on non-selective primary plates from sputum.
Therefore, any rapid molecular screening method should
be encouraged to detect low copy numbers of organisms
in the early stages of colonization/infection, where the
main value of this diagnostic assay is in the rapid screen-
ing of patients with no or an intermittent history of Pseu-
domonas  colonization. Although such assays are not
generally available in most clinical diagnostic laborato-
ries, these laboratories generally do have access to such
technology at regional specialist microbiology centres and
it may therefore be prudent to establish routine analysis of
children's sputum, particularly from patients with no or
an intermittent history by culture of Pseudomonas coloni-
zation, at annual review. Furthermore, it is very important
to follow up any such patients, which demonstrate a PCR
+ve/culture -ve finding from their sputum, in order to
establish whether there is transient infection in patients,
which never result in established colonization leading to
chronic infection. Additionally, it is important to monitor
such PCR +ve/culture -ve patients in terms of optimal
antibiotic management and infection control.
Table 2: Comparison of conventional culture with molecular detection of Pseudomonas aeruginosa from the sputum of adult CF patients
PCR (OprL) PCR (exotoxin A) Culture Frequency of patients (%)
+++ 2 2  ( 3 8 . 6 % )
+-+ 3  ( 5 . 3 % )
--+ 5  ( 8 . 8 % )
++- 3  ( 5 . 3 % )
+-- 7  ( 1 2 . 3 % )
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Overall, our study demonstrated that molecular assays for
the detection of P. aeruginosa were able to detect P. aerugi-
nosa at an early stage, on average 4.5 months sooner than
culture detection. However, it remains unclear what this
"window of opportunity" potentially offers in terms of a
decrease in P. aeruginosa-associated morbidity and
mortality.
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